| abstract |
A vaccine effective against Marek's disease virus (MDV)ncomprises (a) an MDV attenuated by virtue of being TK - or (b) anhost expressing an MDV antigen, namely the respective MDVnhomologues of the HSV gB, gC, gD or gH glycoproteins (ornantigenic parts thereof) or the respective MDV homologues ofnthe HSV-1 immediate early genes IE-68 or IE-175. The host maynbe a herpes virus of turkeys (HVT), more particularly HVT innwhich the MDV antigen is inserted in the HVT homologue of thenHSV gC gene, the ribonucleotide reductase (large subunit) genenor the thymidine kinase (TK) gene. |